Recombinant Human Probable G-protein coupled receptor 34 (GPR34)

What is GPR34 and what are its key structural characteristics?

GPR34 is an X-chromosomally encoded 7-transmembrane G-protein coupled receptor that regulates key biological functions including cellular growth, motility, apoptosis, and gene transcription . It belongs to the P2Y receptor family and has been implicated in the progression of several cancers . The receptor contains important structural elements including phosphorylation motifs in its C-terminus that are crucial for receptor desensitization following ligand binding . Notably, the first intracellular loop contains a tribasic RKR motif which functions as a key topogenic signal determining the orientation of the first transmembrane domain .

What is the natural ligand for GPR34 and how is it generated?

Lysophosphatidylserine (LysoPS) has been identified as the primary ligand for GPR34 . LysoPS is generated through the hydrolysis of phosphatidylserine (PS) by phospholipase enzymes. Specifically, phospholipase A1 (PLA1) catalyzes the synthesis of 2-acyl-LysoPS, while phospholipase A2 (PLA2) mediates the production of 1-acyl-LysoPS . Both forms can activate GPR34, though 2-acyl-LysoPS appears to be more potent . The metabolism of phosphatidylserine on apoptotic cells by phospholipases released from inflamed tissues represents a potential physiological mechanism for GPR34 activation in disease conditions.

What is the expression pattern of GPR34 in normal tissues?

GPR34 shows a ubiquitous expression pattern in both murine and human tissues . More detailed analyses demonstrate GPR34 expression in specific cell lineages, particularly those of myeloid origin, including:

• Myeloid progenitor cell line HL-60

• K562 cells and WEHI-3B cells

• The macrophage cell line RAW 264.1

• The murine mast cell line P815

This expression pattern suggests a granulocytic/monocytic distribution that is consistent with the ubiquitous expression observed in tissues .

How is GPR34 implicated in cancer progression?

Several studies have documented elevated expression levels of GPR34 in multiple malignancies, including:

• Cervical cancer

• Metastatic melanoma

• MALT lymphoma

• BCR/ABL-positive leukemia

• Gastric cancer

• Colorectal cancer

GPR34 plays essential roles in tumor development and progression across these cancer types. Mechanistically, overexpression of GPR34 in lymphoma and HeLa cells results in phosphorylation of ERK, PKC, and CREB; induces CRE, AP1, and NF-κB-mediated gene transcription; and increases cell proliferation . In gastric cancer specifically, GPR34 promotes proliferation of HGC-27 cells via the PI3K/AKT pathway .

How do GPR34 mutations contribute to salivary gland MALT lymphoma?

GPR34 translocation and mutation are specifically associated with salivary gland MALT lymphoma (SG-MALT-lymphoma) . The majority of GPR34 mutations in this context are clustered in the C-terminus of the receptor, resulting in truncated proteins that lack the phosphorylation motif important for receptor desensitization . Functional studies have demonstrated that:

• GPR34 Q340X truncation mutants confer significantly increased resistance to apoptosis and greater transforming potential than the wild-type receptor

• The truncation mutant exhibits significantly delayed internalization after ligand stimulation

• GPR34 truncation mutants show enhanced signaling capacity, particularly for CRE, NF-κB, and AP1 reporter activities

• These effects are amplified in the presence of ligand (LysoPS) stimulation

These findings together provide a mechanistic link between GPR34 mutations and the development of SG-MALT-lymphoma.

What in vitro models are available for studying GPR34 function?

Researchers have developed several in vitro models to study GPR34 function:

• Stable knockdown models: GPR34 knockdown cell lines, particularly in cancer cell lines like LS174T colon cancer cells, allow for studying the effects of GPR34 reduction on cell proliferation, apoptosis, and colony formation .

• Isogenic expression systems: Isogenic Flp-InTRex293 cell lines that stably express a single copy of GPR34 or its various mutants enable controlled comparative functional studies . These systems allow for:

  • Apoptosis resistance assays

  • Transforming potential assessments

  • Receptor internalization studies

  • Multiple signaling pathway analyses using reporter assays

• Antibody blocking approaches: GPR34 monoclonal antibody (Mab) blocking provides another method to investigate the functional importance of GPR34 in cancer cell proliferation .

• Recombinant expression systems: COS-7 cells can be transiently co-transfected with GPR34 constructs and chimeric G proteins (such as Gαqi4) to study specific pathway activation and inositol phosphate accumulation .

What assays can be used to study the effects of GPR34 on cellular proliferation?

Multiple complementary assays have been employed to characterize the effect of GPR34 on cancer cell proliferation:

• CCK-8 assay: This colorimetric assay is used to measure cell viability and proliferation in GPR34 knockdown or overexpression models .

• Colony formation assay: This technique assesses the ability of cells to form colonies, providing insights into the long-term effects of GPR34 modulation on proliferative capacity .

• Xenograft tumor growth models: In vivo models using immunocompromised mice can evaluate the effects of GPR34 manipulation on tumor growth, providing a more comprehensive understanding of its role in cancer progression .

• Reporter gene assays: Dual luciferase reporter assays can measure the activation of proliferation-related transcription factors downstream of GPR34, such as CRE, AP1, and NF-κB .

How can GPR34 signaling pathways be experimentally evaluated?

Several approaches can be used to investigate the signaling pathways activated by GPR34:

• Dual luciferase reporter assays: These assays can measure the activation of multiple signaling pathways including:

  • CRE (cAMP/PKA pathway)

  • NF-κB

  • AP1 (MAPK/JNK pathway)

  • SRF-RE (RhoA pathway)

  • SRE (MAPK/ERK pathway)

  • ISRE, TCF/LEF-RE, and NFAT-RE pathways

• Western blot analysis: This technique can detect the phosphorylation status of downstream signaling molecules such as ERK, PKC, CREB, and AKT .

• Cyclic AMP measurements: These can be performed using technologies like AlphaScreen® to evaluate G protein-dependent signaling .

• Phospholipase activity assays: Commercial assays can measure PLA2 activities in cells expressing GPR34 or its mutants, and free fatty acid release can be measured to assess combined PLA1 and PLA2 activities .

How do GPR34 mutations affect receptor function and signaling?

Different GPR34 mutations exhibit distinct functional effects:

• GPR34 Q340X truncation mutation:

  • Significantly delays receptor internalization after ligand stimulation

  • Enhances resistance to apoptosis

  • Increases transforming potential

  • Significantly activates CRE, NF-κB, and AP1 reporter activities, particularly with ligand stimulation

  • Shows the highest level of associated phospholipase activities

  • Has a higher predicted binding probability to Gαi3, Gαo, and Gα15 G-proteins

• GPR34 D151A mutation:

  • Activates NF-κB and AP1 reporter activities, though to a lesser extent than Q340X

  • Shows enhanced sensitivity to ligand stimulation

  • Exhibits increased phospholipase activities compared to wild-type

• GPR34 R84H mutation:

  • Shows no apparent difference from wild-type in reporter activities regardless of ligand stimulation

  • Affects the tribasic RKR motif in the first intracellular loop

  • The conservative amino acid replacement may explain its lack of major functional impact in standard assays

What is the relationship between GPR34 and lymphoepithelial lesions in salivary gland MALT lymphoma?

Research has revealed a potential paracrine stimulation model connecting lymphoepithelial lesions (LELs) to salivary gland MALT lymphoma via GPR34:

• Phospholipase A1 is abundantly expressed in the duct epithelium of salivary glands and those involved in LELs .

• PLA is released by LELs and hydrolyzes phosphatidylserine exposed on apoptotic cells, generating lysophosphatidylserine (LysoPS), the ligand for GPR34 .

• LysoPS then provides paracrine stimulation to malignant B cells expressing GPR34, particularly those with activating mutations .

• This creates a microenvironment that promotes lymphoma development and progression through enhanced GPR34 signaling .

This model provides a mechanistic explanation for the specific association of GPR34 genetic alterations with salivary gland MALT lymphoma.

What methods can be used to generate and validate GPR34-deficient animal models?

GPR34-deficient mouse models can be generated through the following approach:

• Construction of a conditional GPR34 knockout allele using a targeting vector containing:

  • A neomycin cassette flanked by two loxP sites

  • A third loxP site inserted into the 5' region of GPR34

• Homologous recombination in ES cells, followed by:

  • Screening for neomycin-resistant ES cells

  • Injection of positive ES cell clones into blastocysts

  • Breeding of chimeric offspring into the desired genetic background (e.g., C57BL/6)

• Validation of the knockout through:

  • PCR verification of correct homologous recombination

  • Sequencing of PCR products containing sequences of the targeting construct and genomic flanking regions

  • Verification of proper deletion of the GPR34 coding sequence

• Generation of complete GPR34-deficient mice by breeding female heterozygous mice carrying the mutant loxP GPR34-Neo cassette locus with homozygous male EIIa-Cre mice .

These GPR34-deficient models can then be used to study the receptor's physiological functions and its role in disease processes.

What are the most promising therapeutic applications of GPR34 research?

Based on current research findings, GPR34 represents a potential therapeutic target in multiple cancers, particularly:

• Colorectal cancer, where high GPR34 expression correlates with poorer patient survival .

• Salivary gland MALT lymphoma, where specific GPR34 mutations enhance receptor signaling and contribute to lymphoma development .

• Other cancers including cervical cancer, metastatic melanoma, and gastric cancer, where GPR34 overexpression has been documented .

Therapeutic approaches could include:

• Development of GPR34 antagonists to block receptor signaling

• Targeting downstream pathways activated by GPR34 (PI3K/AKT, MAPK/JNK)

• Inhibition of PLA1/2 to reduce production of the GPR34 ligand, lysophosphatidylserine

• Monoclonal antibodies against GPR34 to block receptor function

What key questions remain to be addressed in GPR34 research?

Despite significant advances, several important questions about GPR34 biology remain:

• The precise physiological roles of GPR34 in normal tissues and immune function

• The mechanisms by which GPR34 overexpression or mutation drives specific cancer types

• The complete G-protein coupling profile of GPR34 and how this might vary across different tissues

• The potential for targeting GPR34 or its signaling pathways for therapeutic benefit in cancer

• Whether GPR34 plays different roles in different stages of cancer progression

• How GPR34 signaling interacts with other oncogenic pathways in cancer cells